drugset
drugset / Trial / NCT00073580

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580 ↗

Phase 3 Completed 88 enrolled The Medicines Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery.

Timeline

Start
2003-10
Primary completion
2005-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiomax Unknown 0.2 mg/kg Intravenous
Subject Angiomax Unknown 1.75 mg/kg Intravenous

Indications

heart disorder thrombocytopenia thrombotic disease